Maximum Tolerated Dose

Related by string. * maxi mum . maximums . MAXIMUM . Maximums : Maximum sustained winds . Maximum Tender Amount . Maximum Sustained Winds . Maximum Tender Offer / Tolerating . TOLERATED . tolerating : tolerated dose MTD . maximally tolerated lipid lowering . tolerating homosexuality / DO Se . DOSE . Doses : mg kg dose . label dose escalation . dose escalation study * Maximum Tolerated Dose MTD *

Related by context. All words. (Click for frequent words.) 65 oral ridaforolimus 65 phase IIb clinical 64 Phase 2a trial 64 phase IIb trial 64 phase Ib 63 Phase Ib 63 dose escalation 63 Dose escalation 63 dose cohort 63 Phase IIIb clinical 63 bicifadine 63 phase IIb study 63 Phase 1b trial 63 BRIM3 62 lintuzumab 62 Phase 2b study 62 Phase IIa trial 62 pharmacodynamic effects 62 elotuzumab 62 Phase Ib clinical 62 forodesine 62 randomized Phase IIb 62 MAGE A3 ASCI 62 eltrombopag 61 tolerated dose MTD 61 phase IIb 61 Phase 2b trial 61 phase IIa 61 TOLAMBA 61 Fibrillex TM 61 sitaxsentan 61 PROMACTA 61 Phase 1b 61 enzastaurin 61 ZOLINZA 61 alvespimycin 61 ORENCIA ® 61 APTIVUS 61 eritoran 61 axitinib 61 Darusentan 61 elagolix 61 mg/m2 cohort 60 plasma pharmacokinetics 60 Phase IIB 60 Phase Ia 60 Zybrestat 60 PEG SN# 60 Phase Ib II 60 pharmacodynamic PD 60 riociguat 60 vidofludimus 60 SYMMETRY trial 60 Aclidinium 60 Phase 1b dose escalation 60 teduglutide 60 AEG# 60 registrational 60 trastuzumab DM1 60 Phase 2b Clinical Trial 60 brivaracetam 60 CR# vcMMAE 60 Phase Ib study 60 HGS ETR1 60 AQ4N 60 dosing cohort 60 budesonide foam 60 Viramidine 60 IIa trial 60 cobiprostone 60 phase IIa clinical 59 fosbretabulin 59 Phase 1a 59 Phase IIb trials 59 dose cohorts 59 DLTs 59 HGS ETR2 59 Nuvion 59 SUCCEED trial 59 BENICAR HCT 59 PXD# 59 Phenoptin 59 MEND CABG II 59 RSD# oral 59 PEG PAL 59 Phase #b/#a 59 limiting toxicity 59 UPLYSO 59 Cloretazine 59 MERLIN TIMI 59 PSMA ADC 59 multicenter Phase II 59 Iloperidone 59 IMC A# 59 Amrubicin 59 Phase IIb clinical 59 rALLy trial 59 Phase III 59 CIMZIA TM 59 EGFR TKI 59 registrational trial 59 vismodegib 59 PRT# 59 mapatumumab 59 Phase 2a clinical 59 SAR# [004] 59 confirmatory clinical 59 R#/MEM # 59 oral methylnaltrexone 59 Phase IIb Clinical Trial 59 glufosfamide 59 EDEMA3 59 Ophena TM 59 Phase IIIb 59 MGd 59 rindopepimut 58 pharmacokinetic PK study 58 deforolimus 58 samalizumab 58 INCB# [001] 58 midstage clinical 58 ENDEAVOR IV 58 PRECISE Trial 58 SVR# 58 Virulizin ® 58 ruboxistaurin 58 randomized Phase 2b 58 pharmacokinetics PK 58 prospectively defined 58 ORENCIA R 58 Bicifadine 58 viral kinetic 58 EMPHASIS HF trial 58 Cimzia TM 58 viral kinetics 58 alvimopan 58 huN# DM1 58 Ereska 58 enoximone 58 huC# DM4 58 multicenter randomized placebo controlled 58 GALNS 58 octreotide implant 58 mGluR5 NAM 58 Corlux 58 CIMZIA TM certolizumab pegol 58 generation antisense inhibitor 58 cannabinor 58 ACTEMRA TM 58 EOquin TM 58 BRIM2 58 Pivotal Phase III 58 vicriviroc 58 Tocosol Paclitaxel 58 INCB# [002] 58 estramustine 58 EndoTAG TM -1 58 Prosaptide 58 CIMZIA ™ 58 nalbuphine ER 58 double blinded placebo 58 treatment naive genotype 58 Asentar 58 phase IIIb 58 ISTODAX 58 posaconazole 58 AP# [003] 58 danoprevir 58 velafermin 58 Phase 1a clinical 58 ruxolitinib 58 PDE inhibitor 58 Phase III ALLEGRO 58 mipomersen 58 Mipomersen 58 peg interferon 58 APPRAISE 57 Allovectin 7 R 57 Ozarelix 57 tecarfarin 57 PANVAC VF 57 Golimumab 57 Degarelix 57 efficacy endpoint 57 Phase IIb 57 Phase 2b 57 nab paclitaxel 57 inhaled treprostinil 57 generation purine nucleoside 57 dirucotide 57 vandetanib 57 TACI Ig 57 TMC# [002] 57 ganetespib 57 IMC #B 57 Bezielle 57 Phase III Pivotal 57 PERSEUS 57 PSN# [002] 57 INC# 57 IPL# 57 Cethromycin 57 Archexin 57 HuMax CD4 57 phase 2a 57 oral deforolimus 57 R# #mg BID 57 RELOVAIR ™ 57 Phase IIa 57 PRECISE trial 57 DSMB 57 APEX PD 57 Phase IIa trials 57 confirmatory Phase III 57 Eltrombopag 57 dose escalation phase 57 Aflibercept 57 ascending dose 57 Vicriviroc 57 midstage trials 57 PEARL SC 57 FORTIS M trial 57 galiximab 57 Phase III Clinical Trial 57 HoFH 57 Pivotal Trial 57 CoFactor 57 PEG IFN 57 ENTEREG ® 57 AEGR 57 pradefovir 57 Phase IIb clinical trials 57 EOquin 57 PREGNANT Study 57 Cloretazine R VNP#M 57 pharmacokinetic PK 57 dose escalation Phase 57 CCX# 57 Phase #/#a 57 maximally tolerated dose 57 urocortin 2 57 timepoint 57 initiate Phase 1b 57 STRIDE PD 57 Achieves Primary Endpoint 57 Phase 2b randomized 57 lumiliximab 57 AZD# 57 preclinical pharmacokinetic 57 DSMB recommended 57 ZYBRESTAT 57 dose limiting toxicities 57 ISIS # 57 evaluable subjects 57 Phase #/#a trial 57 ataluren 57 Reverset 57 rALLy 57 IMGN# 57 divalproex sodium 57 Aerovant 57 CA4P 57 Phase 1b clinical 57 ZACTIMA 57 LB# [003] 57 aclidinium 57 multicenter randomized Phase 57 Spiegelmer ® 56 ILLUMINATE 56 Pivotal Phase 56 Phase #b/#a clinical 56 Allovectin 7 ® 56 HCV RESPOND 2 56 Capesaris 56 mTOR inhibition 56 NGX# 56 lomitapide 56 HCD# [002] 56 PAOD 56 ANCHOR trial 56 LibiGel Phase III 56 LymphoStat B 56 GAMMAGARD 56 azilsartan medoxomil 56 GetGoal Phase III 56 multicenter Phase 56 pomalidomide 56 dexanabinol 56 JAK inhibitor 56 anti leukemic 56 ISENTRESS 56 GSK# [002] 56 ongoing Phase 1b 56 ONTAK 56 secondary efficacy endpoints 56 angiographic outcomes 56 Troxatyl 56 EVIZON 56 Panzem R NCD 56 randomized multicenter trial 56 GOUT 56 Toremifene 56 evaluating tivozanib 56 Azedra 56 Omacetaxine 56 KRN# 56 nonclinical studies 56 Targretin 56 THALOMID 56 Pazopanib 56 compound INCB# 56 sapacitabine 56 atrasentan 56 Phase III clinical 56 heavily pretreated 56 dexpramipexole 56 Phase 2a 56 Clolar ® 56 crizotinib PF # 56 rolofylline 56 SPRYCEL ® 56 Pimavanserin 56 Enzastaurin 56 rFVIIa 56 placebo controlled clinical 56 Phase III Trial 56 Oxypurinol 56 mRCC 56 LAF# 56 LEP ETU 56 intravitreal injection 56 multiple ascending dose 56 randomized multicenter Phase III 56 ARIKACE 56 PF # [002] 56 COPERNICUS 56 complete cytogenetic response 56 Pharmacokinetic 56 cetuximab Erbitux 56 PFO migraine 56 FOLOTYN 56 oxypurinol 56 Seliciclib 56 tanespimycin 56 Anturol TM 56 EDEMA3 trial 56 ENDEAVOR III 56 Phase IIb Trial 56 Insegia 56 severe hypercholesterolemia 56 Tracleer R 56 dacetuzumab 56 RLY# 56 relapsed MM 56 SinuNase 56 ENDEAVOR II 56 Hepatotoxicity 56 Meets Primary Endpoint 56 Phase #b/#a trial 56 ALB # 56 Phase 2b Study 56 CHAMPION PLATFORM 56 Tarceva TM 56 aflibercept 56 HuMax EGFr 56 macitentan 56 Kamada AAT 56 AVADO 56 Tolamba 56 intermittent dosing 56 TBC# 56 PRISTIQ 56 edoxaban 56 CRMD# 56 Ambrisentan 56 ocrelizumab 56 refractory acute myeloid 55 oral prodrug 55 Aplidin 55 inhaled iloprost 55 dopamine partial agonist 55 lintuzumab SGN 55 satraplatin Phase 55 Aloxi injection 55 Pharmacokinetic PK 55 Toxicities 55 ibandronate 55 anagrelide 55 Pemetrexed 55 HuMax CD# 55 cediranib 55 doxorubicin docetaxel 55 Tyrima 55 phase IIb III 55 ACAPODENE 55 Vitaxin 55 celgosivir 55 antiangiogenic therapy 55 CALGB # [002] 55 sunitinib 55 ponatinib 55 APTIVUS r 55 APEX AMI 55 OvaRex R 55 Pralatrexate 55 Virulizin R 55 secondary efficacy endpoint 55 Safinamide 55 Exelixis XL# 55 refractory acute lymphoblastic 55 BAY #-# 55 BLA filing 55 Androxal TM 55 CDK inhibitor 55 tolevamer 55 Targretin capsules 55 Phase IIa clinical 55 GLP toxicology studies 55 incyclinide 55 Phase 2b clinical 55 TMC# C# 55 TELCYTA 55 salmeterol fluticasone 55 OMNARIS HFA 55 Subgroup analysis 55 Onyx Pharma 55 AIMM trial 55 Phase IIb trial 55 pertuzumab 55 MyVax personalized immunotherapy 55 varespladib 55 Phase II 55 HBeAg seroconversion 55 PRX # 55 biliary tract cancer 55 OVATURE 55 GSK# [001] 55 dose escalation trial 55 ENRICH trial 55 initiate Phase Ib 55 regorafenib 55 Renal Cell Carcinoma RCC 55 Alzhemed TM 55 PhosLo 55 PA# [002] 55 INCB# [003] 55 mcg BID 55 Traficet EN 55 ADAGIO study 55 Initiate Phase 55 XL# SAR# 55 Trofex 55 PRE SURGE 55 HGS# 55 RezularTM 55 Glypromate 55 ELACYT 55 solanezumab 55 Ixempra 55 AIM HIGH 55 sunitinib Sutent 55 ALISTA 55 obatoclax 55 Zerenex 55 velafermin belinostat 55 SPARLON 55 peginterferon alfa 55 refractory CLL 55 bortezomib Velcade 55 RE SURGE 55 pharmacokinetic equivalence 55 randomized Phase III 55 Elagolix 55 ularitide 55 dextromethorphan quinidine 55 Cmax 55 administered subcutaneously 55 virologic response 55 ARIKACE ™ 55 YERVOY 55 Triolex 55 O PPDS 55 TLK# 55 Apoptone 55 CLIRS 55 pharmacodynamics PD 55 PEGPH# 55 virological response 55 eosinophilic asthma 55 metastatic sarcomas 55 placebo controlled randomized 55 Betaferon R 55 diabetic neuropathic pain 55 MGCD# [001] 55 BZL# 55 APOPTONE 55 TTF Therapy 55 Plicera 55 glatiramer acetate 55 undetectable HBV DNA 55 TORISEL 55 PEG Interferon lambda 55 Dextofisopam 55 dosage regimens 55 resminostat 55 CLARITY study 55 8mg/kg 55 NATRECOR ® 55 noninferiority 55 PROPEL trial 55 tezampanel NGX# 55 GnRH antagonist 55 Solazed 55 confirmatory Phase 3 55 ATL# [001] 55 Efficacy Results 55 corticosteroid dexamethasone 55 Pafuramidine 55 q#d 55 Arranon 55 mg kg dose 55 vosaroxin 55 StemEx 55 receptor tyrosine kinase inhibitor 55 oxycodone CR 55 VP# [004] 55 CINTREDEKIN BESUDOTOX 55 alemtuzumab Campath 55 motesanib 55 undetectable HCV RNA 55 FOLOTYN ® 55 clinical pharmacology studies 55 Raptiva ® 55 baminercept 55 rapid virologic response 55 Phase 2b Trial 55 serum urate 55 lorvotuzumab mertansine 55 PEGylated interferon beta 1a 55 Acute Ischemic Stroke 55 NDA Submission 55 LUX Lung 55 mg/m2 dose 55 pharmacokinetic profile 55 Denufosol 55 refractory NSCLC 55 PROSTVAC VF 55 unblinded 55 investigational humanized monoclonal antibody 55 denufosol 55 reduce serum phosphate 55 neurologic progression 55 mCRC patients 54 Tasimelteon 54 Tanespimycin 54 FOLPI 54 Certolizumab 54 piperacillin tazobactam 54 trabedersen 54 metastatic hormone refractory 54 initiated Phase Ib 54 KIACTA ™ 54 Phase IIB clinical 54 safety tolerability pharmacokinetic 54 pain palliation 54 NVA# 54 Catena ® 54 AMEVIVE 54 ThGRF 54 QNEXA 54 topically administered 54 pharmacokinetic parameters 54 Randomized Phase 54 Zenvia ™ 54 L BLP# 54 VA# [002] 54 apoptosis inducer 54 peginesatide 54 Annamycin 54 TASKi2 54 ziprasidone 54 preclinically 54 Phase 2b clinical trials 54 Genz # 54 multicenter multinational 54 Phase IIIb study 54 ZYBRESTAT TM 54 prospective multicenter randomized 54 prospective randomized placebo 54 Febuxostat 54 IND submission 54 virologic failure 54 alpha#beta# integrin 54 darusentan 54 rNAPc2 54 NV1FGF 54 valopicitabine 54 catheter occlusion 54 lenalidomide dexamethasone 54 Dasatinib 54 DU #b 54 daclizumab 54 motavizumab 54 generation PNP inhibitor 54 CR nPR 54 metastatic CRC 54 canakinumab 54 orally bioavailable 54 oxaliplatin Eloxatin 54 IL# PE#QQR 54 periprocedural MI 54 Gattex 54 initiate Phase IIb 54 plasma uric acid 54 Forodesine HCl 54 metastatic malignant 54 interferon gamma 1b 54 elacytarabine 54 HuLuc# 54 iniparib 54 Carfilzomib 54 antiviral efficacy 54 PRTX 54 DAPT 54 oral treprostinil 54 FTY# 54 imetelstat 54 maribavir 54 μg dose 54 Phase III HEAT 54 Solid Tumors criteria 54 pediatric pontine glioma 54 metastatic renal cell 54 Azixa 54 virus HCV protease inhibitor 54 PROCHYMAL 54 Ocrelizumab 54 subanalysis 54 systemically administered 54 RSD# 54 EDEMA4 54 NP2 Enkephalin 54 taribavirin 54 Alfimeprase 54 ITAX 54 ZYBRESTAT fosbretabulin 54 II Clinical Trial 54 randomized multicenter 54 ALN VSP Phase 54 mucosal healing 54 Chemophase 54 inhaled AAT 54 telaprevir VX 54 placebo controlled Phase 54 orBec 54 pexelizumab 54 bardoxolone 54 LUMINATE 54 Zenvia Phase III 54 AVE# 54 EXJADE 54 nonrandomized 54 systemic ALCL 54 briakinumab 54 Oglemilast 54 Dacogen decitabine 54 ADVANCE PD 54 pharmacokinetic interactions 54 clevidipine 54 OXi# 54 MDV# 54 Pivotal Clinical Trial 54 neratinib 54 morphometric vertebral fractures 54 Nasulin 54 Dose Escalation 54 COMFORT II 54 omacetaxine mepesuccinate 54 IRESSA 54 Dose Ranging Study 54 afatinib 54 MYDICAR 54 COPEGUS 54 mertansine 54 SCH # 54 Welchol 54 imatinib therapy 54 pharmacodynamics 54 Adalimumab 54 recurrent glioblastoma multiforme 54 Zenvia TM 54 refractory AML 54 Phase IIA 54 investigational monoclonal antibody 54 cEVR 54 PreCISe study 54 Onrigin 54 Pivotal Study 54 urate lowering 54 cell lymphoma CTCL 54 Brentuximab Vedotin SGN 54 eculizumab therapy 54 Omnitarg 54 teriflunomide 54 Sulonex 54 Xelox 54 mCRPC 54 Study #CL# 54 rALLy clinical trial 54 Telintra 54 SPIRIT FIRST 54 antitumor activity 54 PF # [001] 54 Huntexil 54 SILENOR TM 54 CCR5 antagonist 54 HCV SPRINT 54 ALSYMPCA 54 TRANSFORMS 54 ozarelix 54 eniluracil 54 Phase 2b kidney transplant 54 subgroup analyzes 54 PLK1 SNALP 54 unblinding 54 tocilizumab 54 TRO# 54 Azedra TM 54 MADIT II 54 stated Michelle Berrey 54 EMBEDA ™ 54 crofelemer 54 multicenter randomized controlled 54 HBeAg + 54 Voreloxin 54 DCCR 54 IIa trials 54 VELCADE melphalan 54 Phase III trials 54 assessing T DM1 54 Multiple Ascending Dose 54 CIP TRAMADOL ER 54 Itopride 54 MEND CABG 54 PREOS 54 Study NX# 54 AZILECT ® 54 JAK2 inhibitor 54 RECIST Response Evaluation Criteria 54 Dacogen injection 54 CLL SLL 54 Avastin adjuvant 54 pharmacodynamic profiles 54 phase Ib clinical 54 blinded randomized placebo controlled 54 refractory gout 54 ARDIS 54 QTc prolongation 54 Ranolazine 54 SLx 54 Prostate AdenoCarcinoma Treatment 54 active comparator 54 orally administered inhibitor 54 Onconase 54 S/GSK# 54 TASKi3 54 Personalized Immunotherapy 54 favorable tolerability 54 BCIRG 53 Zemplar Capsules 53 trial evaluating PRX# 53 randomized controlled Phase 53 RG# [001] 53 ELND# 53 Somatuline R Depot 53 DEXILANT 53 PDE# inhibitors 53 NSABP C 53 masked placebo controlled 53 schizophrenia CIAS 53 Stedivaze 53 Aurexis 53 Octreolin 53 RAPTIVA 53 albiglutide 53 tezampanel 53 sustained virological response 53 EMPOWER Study 53 PCK# 53 NATRECOR R 53 R lenalidomide 53 ARCALYST ® 53 CCR5 mAb 53 Desmoteplase 53 Pruvel 53 non nucleoside inhibitor 53 RELIANT Trial 53 Matrix Phase 2b 53 tipranavir 53 OPT CHF 53 initiate Phase 2b 53 Telcyta 53 squalamine 53 Ventavis 53 GVAX 53 atazanavir ritonavir 53 plus dexamethasone 53 pharmacodynamic properties 53 AIR CF1 53 SILENOR 53 OHR/AVR# 53 tesmilifene 53 XL# [003] 53 apremilast 53 FOLFOX6 53 laquinimod 53 senicapoc 53 Prestara 53 PRADAXA 53 prucalopride 53 alkylating agent 53 COSTAR II 53 eprotirome 53 fosamprenavir 53 AZILECT R 53 cangrelor 53 Prodarsan 53 MAXY alpha 53 OMP #M# 53 AzaSite Plus 53 goserelin 53 antiretroviral naive 53 clazosentan 53 serum phosphate levels 53 GRN# 53 Board DSMB 53 isavuconazole 53 refractory chronic lymphocytic 53 palonosetron 53 desvenlafaxine succinate 53 VIRAMUNE XR 53 Cand5 53 Ostarine 53 GLPG# 53 rEV# 53 coadministration 53 CIP ISOTRETINOIN 53 Evoltra 53 pivotal Phase III 53 Laquinimod 53 Phase 2a Clinical Trial 53 Diabetic Macular Edema 53 metastatic HRPC 53 unblind 53 levodopa induced dyskinesia 53 Tolvaptan 53 Specifid 53 ORMD 53 SIMPADICO trial 53 Gliadel Wafer 53 CytoFabTM 53 bendamustine 53 tapentadol ER 53 ALVESCO 53 #D#C# 53 Allovectin 7 53 Serada 53 Androxal ® 53 PROactive study 53 olmesartan 53 abatacept 53 CONSERV 53 non inferiority 53 IMPACT DCM 53 mg RDEA# 53 PS# [001] 53 SNT MC# 53 BRAF inhibitor 53 LEXIVA r 53 analgesic efficacy 53 methylnaltrexone 53 Amoxicillin PULSYS Phase III 53 Hedgehog Pathway Inhibitor 53 perampanel 53 ToGA 53 non metastatic osteosarcoma 53 epoetin alpha 53 PIX# [002] 53 cancer neuroendocrine tumor 53 FASLODEX 53 visilizumab 53 Completes Patient Enrollment 53 ABILIFY ® 53 PEP# [003] 53 Phase III Trials 53 Aurora kinase inhibitor 53 CLIRS trial 53 fondaparinux 53 RE LY trial 53 MEK inhibitor 53 Evoltra ® 53 noninferior 53 tenofovir emtricitabine 53 urinary N telopeptide 53 #mg BID [003] 53 relapsed refractory multiple myeloma 53 sunitinib malate 53 #mg/m# [001] 53 INTEGRILIN 53 Torisel 53 Genentech Rituxan 53 tolerability 53 Phase Ib clinical trials 53 Hedgehog antagonist 53 Initiated Phase 53 JANUVIA 53 QLT# 53 vinflunine 53 bosentan 53 randomized discontinuation trial 53 DEB# 53 oxymorphone ER 53 4mg/kg 53 selective modulator 53 Phase IIb III 53 antibody MAb 53 Icatibant 53 refractory metastatic colorectal cancer 53 PREZISTA r arm 53 Antitumor Activity 53 R adalimumab 53 dose titration 53 Ophena 53 PRIMO CABG 53 telaprevir dosing 53 nucleotide analog 53 KNS # 53 Phase III registrational 53 polymerase inhibitor 53 TELINTRA 53 dose escalation study 53 Pegasys plus Copegus 53 maximal tolerated 53 RE LY ® 53 Fidaxomicin 53 Upcoming Milestones 53 relapsed multiple myeloma 53 Increlex R 53 Aliskiren 53 pharmacokinetic studies 53 TroVax 53 LymphoStat B TM 53 TroVax ® 53 reslizumab 53 HspE7 53 EVIZON TM 53 torezolid phosphate 53 placebo controlled Phase III 53 Cinquil 53 KRAS status 53 binary restenosis 53 IIb clinical trial 53 COPD exacerbations 53 INVEGA ® 53 ALT elevations 53 Fodosine 53 ARCOXIA 53 LT NS# 53 inhibitor RG# 53 VISICOL 53 Phase III pivotal 53 glucagon receptor 53 Pharmacokinetics PK 53 novel VDA molecule 53 Initiates Phase III 53 gemcitabine cisplatin 53 cetrorelix 53 Talactoferrin 53 hematological parameters 53 BRILINTA 53 recurrent malignant glioma 53 RAPTIVA R 53 GLP1 agonist 53 AERx iDMS 53 Sensipar 52 glucokinase activator 52 EVEREST II 52 DASISION 52 BROVANA 52 Viprinex TM 52 CRLX# 52 Canvaxin 52 APEX AMI trial 52 ezogabine 52 bevirimat Study 52 Free Survival PFS 52 dose escalation clinical 52 Ziprasidone 52 6R BH4

Back to home page